wire - news in brief

« BACK

Pharmacology



Results 201 - 250 of 1656.


Health - Pharmacology - 16.09.2020
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
HIV continues to be a major global health issue, having claimed almost 33 million lives.

Pharmacology - Health - 16.09.2020
Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1   Adjuvant treatment with

Pharmacology - Health - 14.09.2020
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD     The update includes the additional characterization of retinal vasculitis a

Pharmacology - Health - 11.09.2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naļve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naļve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di

Health - Pharmacology - 08.09.2020
"These results are crucial for the future corona vaccination strategy"
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.

Pharmacology - Health - 07.09.2020
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale

Pharmacology - Health - 02.09.2020
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo

Pharmacology - Health - 30.08.2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer

Pharmacology - Health - 26.08.2020
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.

Pharmacology - Health - 22.08.2020
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg

Pharmacology - Health - 20.08.2020
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros

Pharmacology - Health - 17.08.2020
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o

Pharmacology - Health - 11.08.2020

Pharmacology - Health - 10.08.2020
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants

Pharmacology - Health - 05.08.2020
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1  

Pharmacology - Health - 04.08.2020
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate   Kymriah previously receive

Pharmacology - Health - 03.08.2020
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1   Modera

Health - Pharmacology - 29.07.2020
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care   Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.

Pharmacology - Health - 27.07.2020
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,

Health - Pharmacology - 15.07.2020
Drones to Deliver Tuberculosis Drugs in Madagascar
Drones to Deliver Tuberculosis Drugs in Madagascar
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.

Pharmacology - Health - 13.07.2020
New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest

Health - Pharmacology - 06.07.2020
"We have the here and now. That’s all we really have."
Acceptance and Commitment Therapy (ACT) is still a relatively young approach from behavioral therapy, but has already proven itself in the treatment of a wide range of mental disorders.

Health - Pharmacology - 30.06.2020
Meeting challenges through basic research
Meeting challenges through basic research
Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception.

Pharmacology - Health - 26.06.2020
Novartis Cosentyx gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis   CHMP opinion based on two Phase III studies showing Cosentyx provides fast and stro

Pharmacology - Health - 26.06.2020
Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglo

Health - Pharmacology - 24.06.2020

Health - Pharmacology - 23.06.2020
Breast Cancer Diagnostics: Spin-off Artidis announces successful clinical trial
Breast Cancer Diagnostics: Spin-off Artidis announces successful clinical trial
The company Artidis, a University of Basel spin-off, has announced that it developed a test procedure that can detect breast cancer with a very high sensitivity. This is demonstrated by a clinical trial that investigated whether a nanomechanical biomarker of tissue samples is suitable for the diagnosis of breast cancer.

Health - Pharmacology - 22.06.2020
Computational pharmacology to combat the coronavirus
The ongoing COVID-19 pandemic has hit the world population hard, spreading throughout the globe since the beginning of the year and claiming more than 450,000 victims. The entire scientific community is engaged in an unprecedented effort to curb the progression of the disease, for which no specific cure is yet available.

Pharmacology - Life Sciences - 19.06.2020